Targeting Trends in Diabetes Testing
Testing for, monitoring, and controlling diabetes continues to become more robust, cost-effective, and nuanced.
Read MorePosted by Chris Wolski | Aug 30, 2021 | Diabetes & Metabolic Diseases |
Testing for, monitoring, and controlling diabetes continues to become more robust, cost-effective, and nuanced.
Read MorePosted by Chris Wolski | Aug 24, 2021 | Unknown Origin & Other Cancer Types |
Siemens Healthineers’ Enhanced Liver Fibrosis (ELF) Test was granted marketing authorization under the De Novo review pathway.
Read MorePosted by Chris Wolski | Aug 19, 2021 | Cancer |
llumina, Inc. has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers.
Read MorePosted by Chris Wolski | Aug 19, 2021 | Kidney Disease |
Despite their higher risk of chronic kidney disease, people with hypertension or diabetes usually are not given a protein in the urine test.
Read MorePosted by Chris Wolski | Aug 16, 2021 | Covid 19 |
Researchers examined data from a large-scale surveillance program in Madurai, Tamil Nadu, COVID-19 infection and mortality.
Read More